Wegovy for Adolescents Ages 12 to 17: Off-Label Use, Evidence, and What Families Need to Know

What "Off-Label" Actually Means for This Age Group

The phrase "off-label Wegovy in adolescents" is used loosely, and the distinction matters clinically. Novo Nordisk received FDA approval in December 2022 to extend the Wegovy indication to patients aged 12 and older with an initial BMI at or above the 95th percentile for age and sex. That approval was not a pediatric extrapolation. It was based on a dedicated randomized controlled trial in this cohort.

Prescribers face genuine off-label territory, though, when a patient is 12 to 17 but does not meet the approved BMI threshold, when a clinician wants to use the drug for overweight-related cardiometabolic risk before obesity develops, or when dosing strategies diverge from the label.

Why the Terminology Gets Blurry

The FDA pediatric label mirrors the adult obesity label in its BMI cutoff logic but swaps the adult threshold of 30 kg/m2 for the age-and-sex-adjusted 95th-percentile criterion. A 14-year-old with a BMI at the 92nd percentile and early insulin resistance does not qualify under the label, even if a clinician judges treatment to be medically appropriate. That gap between guideline-endorsed individualized care and the regulatory approval boundary is where most off-label conversations begin.

The American Academy of Pediatrics 2023 Clinical Practice Guideline states directly: "Clinicians should offer adolescents 12 years and older with obesity (BMI greater than or equal to 95th percentile) weight loss pharmacotherapy, according to medication indications, risks, and benefits, as an adjunct to health behavior and lifestyle treatment." [1] That language maps to the approved indication. Younger ages and lower BMI percentiles remain genuinely off-label.

The Regulatory Timeline Worth Knowing

Wegovy received its original adult approval in June 2021 for chronic weight management. The supplemental pediatric approval came 18 months later in December 2022, making semaglutide the first GLP-1 receptor agonist approved for weight management in adolescents. [2] Before December 2022, any use in patients under 18 was off-label. Clinicians who treated teens in 2021 or early 2022 were operating entirely outside the label, which shaped the real-world experience that now informs cautious off-label practice in edge cases.

STEP TEENS: The Core Evidence Base

The key data come from STEP TEENS, a 68-week phase 3a randomized, double-blind, placebo-controlled trial published in the New England Journal of Medicine in 2022. [3] Understanding its design clarifies both what is known and what remains uncertain for off-label scenarios.

Trial Design and Population

STEP TEENS enrolled 201 adolescents aged 12 to 17 with a BMI at or above the 95th percentile or above 30 kg/m2 with at least one weight-related comorbidity. Participants were randomized 2:1 to subcutaneous semaglutide 2.4 mg once weekly or placebo, with both groups receiving lifestyle counseling. Mean baseline BMI was 37.9 kg/m2 in the semaglutide group.

The trial excluded participants with type 2 diabetes and those with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2. Those exclusions carry forward to real-world prescribing decisions.

What the Numbers Show

The results were striking. At week 68, participants in the semaglutide group achieved a mean 16.1% reduction in BMI, compared with a mean 0.6% increase in the placebo group. That translated to a difference of 16.7 percentage points (P<0.001). [3] Body weight fell by a mean of 14.7% with semaglutide versus a mean increase of 2.7% with placebo.

Cardiometabolic markers also improved. Waist circumference fell by 14.8 cm in the semaglutide group versus 1.5 cm in the placebo group. HbA1c, fasting glucose, triglycerides, and blood pressure all improved to a greater degree in the active treatment arm. [3]

Safety Profile in STEP TEENS

Adverse events largely mirrored the adult experience. Gastrointestinal events, primarily nausea (62% semaglutide vs. 42% placebo), vomiting (42% vs. 18%), and diarrhea (31% vs. 23%), were the most common reasons for dose interruption or reduction. [3] Three participants discontinued due to adverse events. No cases of pancreatitis, thyroid cancer, or serious hypoglycemia were reported during the trial period.

One finding that does not appear in adult trials deserves attention: STEP TEENS tracked self-reported depressive symptoms and suicidal ideation using validated scales, and no statistically significant difference between groups was observed. The trial was not powered to detect rare psychiatric events, so this finding is reassuring but not definitive.

Off-Label Scenarios Clinicians Actually Encounter

The following framework reflects how board-certified pediatric endocrinologists and obesity medicine specialists approach semaglutide decisions outside the approved indication. It is not a substitute for individualized clinical evaluation.

Scenario 1: BMI at the 85th to 94th Percentile (Overweight, Not Obese)

A patient in this weight range has "overweight" by pediatric definitions. The FDA label does not apply. A clinician might consider semaglutide off-label if the patient has significant insulin resistance, hepatic steatosis confirmed on imaging, or a family history of early type 2 diabetes that makes the trajectory medically urgent.

The evidence base for this population is thin. No published RCT has specifically studied semaglutide in adolescents with overweight-only classification. Clinicians drawing on adult data from STEP-1 (N=1,961), where participants required a BMI of 27 kg/m2 or above with at least one comorbidity, can apply an analogous framework to adolescents. [4] That extrapolation is reasonable but speculative.

Before prescribing in this scenario, most pediatric obesity specialists document failure of at least three to six months of structured lifestyle intervention, the specific cardiometabolic risk factors driving the decision, and a detailed informed consent discussion with the patient and their caregivers.

Scenario 2: Ages 10 and 11 (Below the Approved Age Floor)

The FDA label explicitly begins at age 12. Children aged 10 or 11 with severe obesity are a genuinely underserved population. No phase 3 trial has evaluated semaglutide 2.4 mg in this age group. Using it would be off-label in the strictest sense, with no dedicated pediatric pharmacokinetic or safety data.

The Endocrine Society's 2023 Clinical Practice Guideline on pediatric obesity acknowledges that pharmacotherapy may be appropriate for children under 12 in specific clinical circumstances but does not endorse semaglutide specifically for this group given the absent data. [5] Clinicians who choose this path typically do so only within academic centers with access to multidisciplinary teams, including pediatric endocrinology, psychology, and dietetics.

Scenario 3: Post-Bariatric Weight Regain

Some adolescents who undergo sleeve gastrectomy or Roux-en-Y gastric bypass experience significant weight regain within two to five years of surgery. Using semaglutide in this context is not addressed by the pediatric label and represents another off-label application.

Adult data suggest semaglutide can produce meaningful additional weight loss after bariatric procedures, though GI tolerability may differ given altered gastric anatomy. [6] Pediatric-specific data for this scenario do not yet exist.

Scenario 4: Comorbidity-Driven Early Treatment Before Obesity Threshold

A 16-year-old with polycystic ovary syndrome, insulin resistance, and a BMI at the 93rd percentile does not meet the label threshold. A clinician might nonetheless argue that the metabolic trajectory warrants intervention before the patient reaches the 95th percentile and the associated comorbidity burden deepens. This scenario is common in pediatric endocrinology clinics, and clinical judgment must fill the gap that trial data cannot.

Dosing in Adolescents: On-Label and Off

For the approved indication, dosing in adolescents aged 12 and older follows the same titration schedule as adults:

• Weeks 1 to 4: 0.25 mg subcutaneously once weekly
• Weeks 5 to 8: 0.5 mg once weekly
• Weeks 9 to 12: 1.0 mg once weekly
• Weeks 13 to 16: 1.7 mg once weekly
• Week 17 onward: 2.4 mg once weekly (maintenance)

The FDA label permits staying at 1.7 mg if the patient does not tolerate the 2.4 mg dose. [2] There is no approved dose above 2.4 mg per week in any population.

Weight-Based Dosing Considerations

Unlike some pediatric drugs, Wegovy dosing in the 12-and-older age group is not weight-based. The same fixed-dose titration applies regardless of whether a patient weighs 60 kg or 120 kg. This reflects the trial design of STEP TEENS, which used fixed doses across a wide BMI range. Whether lower starting doses might reduce GI burden in smaller adolescents is a reasonable clinical question that has not been studied in an RCT.

Injection Technique and Adherence

Adolescents may require additional coaching on self-injection technique. The autoinjector pen format of Wegovy is the same as the adult device. Data from adult populations show that injection-site rotation and consistent weekly timing reduce local reactions and missed doses. The same principles apply here, though adolescent-specific adherence data are limited.

Growth, Bone Health, and Nutritional Concerns

Adolescence is a critical period for linear growth, bone mineral density accrual, and nutritional development. These concerns are not hypothetical.

Linear Growth

STEP TEENS tracked height velocity over 68 weeks and found no statistically significant difference between groups. [3] Mean height increased by 2.4 cm in the semaglutide group and 2.3 cm in the placebo group. However, 68 weeks is a relatively short window for assessing a process that unfolds over years, and post-marketing surveillance data are still accumulating.

Bone Density

Caloric restriction sufficient to cause weight loss could theoretically compromise peak bone mass accrual if protein and calcium intake are inadequate. No dedicated bone density outcomes were reported in STEP TEENS. Clinicians prescribing semaglutide to adolescents should ensure dietary calcium and vitamin D adequacy and consider baseline and follow-up DEXA scanning in patients with risk factors for low bone density.

Nutritional Deficiencies

Nausea and appetite suppression may reduce total dietary intake. In a growing adolescent, protein intake below 0.8 to 1.2 g/kg/day may compromise lean mass. Dietitian involvement is not optional in this population. The 2023 AAP guideline reinforces that pharmacotherapy should always be paired with structured dietary and behavioral support. [1]

Mental Health Monitoring

The FDA added a class-wide label update for GLP-1 receptor agonists in 2023 noting a potential signal for suicidal ideation, though a causal relationship was not established. [7] Adolescents have baseline vulnerability to depression, anxiety, and disordered eating, making this monitoring obligation more acute than in adult populations.

A clinician prescribing semaglutide to a 14-year-old should complete validated mental health screening at baseline (PHQ-A or equivalent), at each follow-up visit, and any time a caregiver or patient raises a behavioral concern. Weight stigma and body image concerns are particularly prevalent in teens with obesity and can be exacerbated if weight loss expectations are not met or weight plateaus occur.

The Obesity Medicine Association recommends that all adolescent obesity pharmacotherapy occur within a framework that includes at minimum one behavioral health touchpoint every 90 days. [8]

Guideline Positions Across Major Societies

American Academy of Pediatrics

The 2023 AAP Clinical Practice Guideline for Obesity in Children and Adolescents recommends offering weight loss pharmacotherapy to adolescents 12 and older with obesity as an adjunct to lifestyle treatment. [1] The guideline specifically names semaglutide and does not restrict its recommendation to the 95th-percentile threshold exclusively when comorbidities are present.

Endocrine Society

The Endocrine Society's 2023 guideline on pediatric obesity states that GLP-1 receptor agonists "should be considered in the treatment of youth with obesity who have not achieved adequate response to lifestyle interventions alone." [5] The guideline grades this recommendation as strong with moderate evidence.

American Diabetes Association

For adolescents with type 2 diabetes, the ADA Standards of Care do not recommend semaglutide 2.4 mg (the obesity dose) as a first-line agent but note that weight management is an integral part of glucose control. [9] The ADA recommends liraglutide 3 mg as an approved option for adolescents with obesity and type 2 diabetes, and acknowledges semaglutide's emerging role as the evidence base grows.

The Informed Consent Conversation

Prescribing semaglutide off-label to a minor requires consent from a parent or legal guardian in addition to developmentally appropriate assent from the patient. The conversation should address:

1. The distinction between approved use and off-label use for this specific patient
2. What STEP TEENS showed and what it did not measure
3. The GI side-effect profile and how to manage it
4. Growth monitoring and nutritional requirements
5. The plan if treatment is not producing a 5% BMI reduction at 16 weeks
6. Long-term unknowns, including durability of effect after stopping the drug

Weight regain after stopping semaglutide is documented in adult data from the STEP 4 trial, where participants who discontinued semaglutide regained approximately two-thirds of lost weight within 52 weeks. [10] Parents should understand that pharmacotherapy may need to continue indefinitely for sustained effect.

Practical Prescribing Checklist for Off-Label Adolescent Use

The following items reflect standard practice at academic pediatric obesity programs, not a minimum regulatory standard:

• Confirm patient age is 12 or older, or explicitly document rationale if younger
• Document BMI percentile and the clinical factors driving the off-label decision if BMI is below the 95th percentile
• Screen for personal or family history of medullary thyroid carcinoma or MEN2
• Obtain baseline metabolic panel, HbA1c, lipid panel, hepatic function, and thyroid function
• Complete baseline mental health screening with a validated tool
• Refer to or consult dietitian familiar with adolescent nutrition
• Discuss contraception with sexually active female patients, as weight changes may affect hormonal contraceptive efficacy
• Plan first follow-up visit at 4 weeks to assess GI tolerability and injection technique
• Set a 16-week response threshold: if BMI has not decreased by at least 5%, reassess the treatment plan